EGFR and lung carcinoma: In February 2015, we switched from Therascreen to EGFR‐Cobas for EGFR mutation testing when osimertinib was approved for the treatment of patients with T790M‐positive lung cancer who relapsed on prior EGFR‐TKI therapy because only Cobas was approved as a CDx test for the use of osimertinib in patients with T790M mutations.